Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2015 Dec;59(12):7888-90. doi: 10.1128/AAC.02145-15. Epub 2015 Oct 5.

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.

Author information

1
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
2
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali.
3
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Howard Hughes Medical Institute, Chevy Chase, Maryland, USA wbishai1@jhmi.edu.

Abstract

With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).

PMID:
26438491
PMCID:
PMC4649180
DOI:
10.1128/AAC.02145-15
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center